Skip to main content

Table 1 Characteristics of patients included in this meta-analysis

From: The impact of STAT3 and phospho-STAT3 expression on the prognosis and clinicopathology of ovarian cancer: a systematic review and meta-analysis

Study

Country

N pts

Age (years)

p-STAT3+ (%)

STAT3+ (%)

Pathological type

(cancer/

borderline/

benign/

normal)

Histological type

(S/C/E/M)

FIGO stage

(I-II/III-IV)

Tumour grade (G1 + G2/

G3)

LN

(yes/no)

Anti-

body

Scoring method

Cut-off value

Follow-up (months)

Survival analysis

HR estimate

NOS score

Yoshikawa (2018) [20]

Japan

341

16–82 (53 median)

95 (28%)

NR

NR

S144, M60, E52, C85

166/175

NR

NR

RmAb

NR

> 10%

median 58 (1–257)

OS/PFS

HR

8

Yang [21] (2013)

USA

49

41–87 (61 median)

25 (51.02%)

NR

NR

SME47, CU2

16/33

18/31

NR

Ab

E

≥50%

NR

OS

HR

7

Min [22] (2009)

China

50

22–73 (50.6 median)

29 (58%)

44 (88%)

50/NR/20/20

S45, M2, C2, O1

18/32

34/16

9/22

Ab

I,E(P)

1+, ≥10%(P)

NR

OS

K-M

7

Shang [23] (2017)

China

136

21–83 (54 median)

72 (52.94%)

86 (63.23%)

NR

S72, M36, E15, C13

56/80

52/84

59/77

R Ab

EI

≥4

48

OS

HR

8

Rosen [24] (2006)

USA

303

20–86 (58.2 median)

261 (86%)

NR

NR

S232, M6, E33, C15, O36

56/247

14/289

NR

Ab

EI

≥3

median 64 (1–120)

OS

K-M

8

Xiao [25] (2015)

China

40

NR

32 (80%)

NR

40/20/20/NR

NR

NR

12/28

31/9

Ab

EI

≥3

NR

NR

NR

5

Gao [26] (2013)

China

34

30–78 (55.6 median)

NR

28 (82.4%)

34/10/10/NR

S18, M10, E4, C2

12/22

19/15

20/14

RmAb

E

≥6%

NR

NR

NR

5

Wu [27] (2021)

China

130

23–67 (53 median)

NR

90 (69.2%)

130/30/20/NR

NR

47/83

NR

52/78

MAb

EI

> 1+ ≥25%

NR

NR

NR

8

Zhang [28] (2008)

China

56

34–71 (52.5 median)

NR

49 (87.5%)

56/18/35/25

NR

12/44

35/21

32/24

RpAb

EI

≥2

NR

NR

NR

6

Chen [29] (2017)

China

31

NR

10 (32.26%)

NR

NR

S15, M4, E7, C5

10/21

NR

NR

Ab

EI

≥3

NR

NR

NR

8

Li [30] (2020)

China

156

23–73 (50.6 median)

86 (55.13%)

NR

NR

S116, M22, E12, O6

46/110

64/84

43/113

Ab

E

≥50%

median 84 (60–108)

OS/PFS

K-M

7

Yanaihara [31] (2016)

Japan

84

NR

33 (39.29%)

NR

NR

NR

63/21

NR

NR

Ab

EI

> 2

NR

OS/PFS

HR

8

Wouters [32] (2015)

Netherland

101

57.99 median

20 (20%)

NR

NR

S57, M7, E18

27/74

NR

NR

RmAb

EI

≥3

NR

NR

NR

8

Chaluvally_Raghavan [33] (2016)

USA

145

35–88 (58.8 median)

NR

67 (46.2%)

NR

S145

9/136

NR/145

NR

Ab

EI

> 1

NR

OS

K-M

7

Guan [34] (2010)

China

42

37–72 (52 median)

NR

34 (80.95%)

42/NR/25/13

S29, M9, E4

9/33

NR

NR

RAb

EI

≥3

NR

NR

NR

6

Hong [35] (2017)

China

49

42–76 (63.4 median)

NR

34 (69.4%)

49/NR/14/NR

NR

35/14

NR

NR

Ab

EI

≥3

NR

NR

NR

5

  1. N pts number of patients, STAT3 signal transducer and activator of transcription 3, p-STAT3 phospho-STAT3, NR not reported, C clear cell, S serous, E endometrioid, M mucinous, U Undifferentiated, O Others, FIGO International Federation of Gynecology and Obstetrics, LN Lymph node metastasis, M mouse, R rabbit, pAb polyclonal antibody, mAb monoclonal antibody, E extent, I intensity, p phospho-STAT3, OS overall survival, PFS progression-free survival, K-M Kaplan–Meier survival curves, HR hazard ratio, NOS Newcastle–Ottawa Quality Assessment Scale